	A.Un- Audited Financial Results(Provis	ional) for the Qu	arter and Half	Year ended 30	h September 2	014	
(Rs. in Le							
			Unaudited		Unaudited		Audited
1		Quarter ended			Half year ended		Year Ended
Sr. No.	Particulars			Correspondi		[
	, -, -, -, -, -, -, -, -, -, -, -, -, -,			ng 3 months		Year to date	
		3 months	3 months	ended in the previous	figures for Current	figures for	Previous
		ended	ended	period		the previous period ended	accounting year ended
		30.09.14	30.06.14	30.09.13	30.09.14	30.09.13	31.03.14
1	Sales/Income from operation(Net of Excise duty)	4084,93	3855.81	2812.68		4648.15	12231.97
2	Other Operating Income	264.97	7.74	8.61	272.71	17.54	35.78
3	Total Net Income from Operation	4349.90	3863.55	2821.29			12267.75
4	Expenditure						
	(a) Increase / decrease in stock in trade & work in progress	(24.4.57)	/450.40\	(440.00)	1000 -01	(554.57)	
	(b) Consumption of raw materials	(214.57) 2964.08	(152.16) 2765.71	(116.08) 1788.18	(366.73) 5729.79	(501.07) 3574.73	(544.63) 8374.88
	(c) Employee Benefits	275.09	253,18	266.80		511.07	1024.55
	(d) Depreciation	93,63	106.90				401.05
	(e) Other expenditure	745,16	641.06	630.38		1092.14	2436.55
	(f) Total	3863.39	3614.69	2668.07	7478.08	4874.15	11692.40
	Profit(+)/Loss(-) from operations before Other income, Finance cost and Exceptional Items(3-4)	486.51	240 00	453.00	705 07	(222.42)	C7C A-
	Other Income	2.69	248.86 2.19	153.22 0.00	735.37 4.88	(208.46) 1.98	575.35 8.23
	Profit (+) / Loss (-) from ordinary activities before Finance	2.00	2.10	3.00	4.00	1.80	0.23
	Cost & Exceptional Items(5+6)	489.20	251.05	153,22	740.25	(206.48)	583.58
	Finance Cost	273.64	271.35	250.13	544.99	476.99	974.21
	Profit(+)/Loss(-) from ordinary activities after Finance cost but before Exceptional Items(7-8)		(00.00)	,,,,,,			
	Exceptional Items	215.56 0.00	(20,30)	(96.91) 0.00	195.26 0.00		(390.63)
	Profit(+)/Loss(-) before Tax (9-10)	215.56	(20.30)	(96.91)	195.26		(390.63)
12	Tax Expenses(incl Deferred Tax)	15.00	0.00	0.00			(86.71)
	Net Profit(+)/Loss(-) after Tax (11-12)	200.56	(20.30)	(96.91)	180.26		(303.92
14	Extraordinary Items	0.00	0.00	0.00			0.00
	Net Profit(+)/Loss(-) for the period(13-14) Paid up Equity Share Capital (face value Rs.10/-each)	200.56 1317.82	(20.30) 1317.82	(96.91)	180.26		(303.92)
<u>'</u> "	Reserves excluding Revaluation Reserves as per	1317.02	1317.02	1317.82	1317.82	1317.82	1317.82
12	balance sheet of previous accounting year.	0.00	0.00	0.00	0.00	0.00	1004,48
13	Earning per share (EPS)						
	(a) Basic and diluted EPS before extraordinary items for						
	the period, for the year to date and for the previous year	4.50	(0.45)				
\vdash	(not to be annualized) (b) Basic and diluted EPS after extraordinary Items for	1.52	(0.15)	(0.74)	1,37	(5.19)	(2.31)
	the period, for the year to date and for the previous year					1	
lacksquare	(not to be annualized)	1.52	(0.15)	(0.74)	1.37	(5.19)	(2.31)
14	Non Promoters Shareholding						,
 	- Number of shares	7628115	7628115	7548453	7628115		7628115
15	Percentage of shareholding Promoters and Promoter group Shareholding	57.88	57.88	57.28	57.88	57.28	57.88
	a) Pledged/ Encumbered						
	Number of Shares	5491228	5491228	5448708	5491228	5448708	5491228
	Percentage of Shares (as a % of the total						
$oxed{eta}$	shareholding of promoter & promoter group	98.94	98.94	96.78	98.94	96.78	98.94
	Percentage of Shares (as a % of the total share capital of the company)	44.64	11.07	44.00		44.55	
	b) Non-encumbered	41.67	41.67	41.35	41.67	41.35	41.67
	Number of Shares	58905	58905	181087	58905	181087	58905
	Percentage of Shares (as a % of the total						
	shareholding of promoter & promoter group)	1.06	1,06	3.22	1.06	3.22	1.06
	Percentage of Shares (as a % of the total share capital of the company)	0.45	A 45	4.07		4.0-	A 4-
	энаге сорнагот те сотрану)	0.45	0.45	1.37	0,45	1.37	0.45
	•	3 Months					
16	Investors Complaints:	ended 30.09.14					
	Pending at the Beginning of the Quarter	30.09.14 Nil					
	Received during the Quarter	Nil					
	Disposed of during the Quarter	Nil					
	Remaining unresolved at the end of the Quarter	Nil					

Notes:

Place: Mumbai

Date: 14.11.2014

- The above results have been reviewed by the Audit Committee and thereafter , were taken on record by the Board of Directors of the Company at their meeting held on 14th,November 2014
- As the Company's business activity falls within a single primary business segment viz Manufacturing of Bulk Drugs "the disclosure requirements of Accounting Standard (AS-17)" Segment Reporting "is not applicable.
- Previous year figure are regrouped wherever necessary.

For MILWANI ASSOCIATES ASSOCIATION OF THE PROPERTY ASSOCIA

(CA Rakes) K. Milwani) Propial oribin 400 002/ Membership No.: 8608 BHARAT NO.: 106406 MO JACCON

On behalf of Board of Directors For Mangalam Drugs & Organics Ltd

Chairman

(Shri Govardhan M.Dhoot)

MANGALAM DRUGS & ORGANICS LTD.



Statement Of Assets & Liabilities (Un-Audited) As at 30th Sept 2014, Required Under Clause 41 Of Listing Agreement

(Rs.In Lacs) S.No. Particulars Half Year ended(Un-Year Ended (Audited) audited) 30.09.2014 31.03.2014 **EQUITY AND LIABILITIES** Shareholders' funds (a) Share capital 1,317.82 1,317.82 (b) Reserves and surplus 1,184.73 1,004.47 Sub Total -Shareholders Funds 2,502.55 2,322.29 Non-current liabilities 4,039.20 (a) Long-term borrowings 4,020.21 (b) Deferred Tax Liabilities (Net) 58.56 58.56 Sub Total -Non-Current Liabilities 4,097.76 4,078.77 Current liabilities (a) Short-term borrowings 2,985.40 3.136.67 (b) Trade payables 1,456.42 2,086.73 (c) Other current liabilities 925.82 919.97 Sub Total -Current Liabilities 5,367.64 6,143.37 TOTAL 11,967.95 12,544.43 ASSETS I) Non-current assets (a) Fixed Assets 5244.43 5338.43 (b) Long-term loans and advances 258.78 239.<u>77</u> Sub Total -Non-Current Assets 5,503.21 5,578.20 Current assets (a) Current Investments 24.01 17.92 (b) Inventories 3,545.74 3,647.76 (c) Trade receivables 2,282.02 2,968.73 (d) Cash and cash equivalents 24.14 10.23 (e) Short-term loans and advances 588.83 321.59 Sub Total -Current Assets 6,464.74 6.966.23 TOTAL 11,967.95 12,544.43

Notes:1) Previous periods/years figures have been regrouped/rearranged wherever necessary.

On behalf of Board of Directors For Mangalam Drugs & Organics Ltd

Place:Mumbai Date: 14.11,2014

For MILWANI ASSOCIATES

(Shri Govardhan M.Dhoot)

Chartered Accountants

(CA Rakesh K. Milwani) Propheto 133, Dr. M. B. Welkar St. Membership No.: 36099 Aumbai 400 002

CA Rakesh K, Milwani
B.Com., L.L.B., FCA,

MILWANI ASSOCIATES

CHARTERED ACCOUNTANTS

18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002. Tel.: 22036132/9821162679 E-mail: rakesh_milwani@hotmail.com

To
The Secretary
Stock Exchange, Mumbai
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

To,
National Stock Exchange of India Limited
"Exchange Plaza",
Bandra - Kurla Complex,
Bandra (E),
Mumbai - 400 051.

LIMITED REVIEW REPORT

We have reviewed the accompanying statement of unaudited financial results of Mangalam Drugs & Organics Ltd. having its registered office at Rupam Building, 3rd Floor, 239 P.D'Mello Road, Near GPO, Mumbai – 400001; for the quarter and half year ended 30th Sept'2014 except for the disclosures regarding 'Public share holding' and 'Promoter and Promoter group share holding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not an audit and accordingly, we do not express such an opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Mumbai

Date : 14th November 2014.

Membershan No.:106405W